Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Antiviral Agents
/ therapeutic use
Australia
/ epidemiology
Cohort Studies
Coinfection
/ epidemiology
Drug Users
Female
HIV Infections
/ complications
Hepacivirus
Hepatitis C
/ drug therapy
Hepatitis C, Chronic
/ complications
Homosexuality, Male
Humans
Incidence
Male
Middle Aged
Prospective Studies
Reinfection
/ epidemiology
Substance Abuse, Intravenous
/ complications
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
16
3
2021
Statut:
ppublish
Résumé
To evaluate changes in injecting and sexual risk behaviours, and hepatitis C virus (HCV) reinfection incidence among people with HIV/HCV coinfection following unrestricted access to direct-acting antiviral therapy in Australia. Prospective observational cohort study (2014-2018). Among people enrolled in the Control and Elimination of HCV from HIV-infected individuals within Australia study, changes in injecting and sexual behaviour were evaluated, including injecting drug use (IDU) in the last 6 months and last month, frequency of IDU and equipment sharing, condom-less anal intercourse with casual male partner(s), and group sex. HCV reinfection incidence was evaluated with follow-up through May 2018. Overall, 272 HIV/HCV antibody-positive participants [median age; 50 years, 96% male, 83% identified as gay and bisexual men (GBM)] had behavioural data at enrolment and follow-up (median 2.91 years) available for analysis. The proportion reporting IDU in the last 6 months remained stable from enrolment (35%) to follow-up (39%). Among GBM, the proportion reporting condom-less anal intercourse with casual partner(s) at enrolment (48%) and follow-up (46%) was also similar. Reinfection was detected in five individuals (all GBM) during total follow-up of 474 person-years for an overall incidence of 1.05 per 100 person-years (95% confidence interval, 0.44-2.53). No change was observed in levels of injecting or sexual risk behaviour for HCV infection following unrestricted access to direct-acting antiviral therapy in an Australian HIV/HCV cohort. Incidence of HCV reinfection was low potentially reflecting high levels of treatment coverage within this population. Continued screening and rapid retreatment of reinfection will be required to maintain progress towards elimination.
Identifiants
pubmed: 32590433
doi: 10.1097/QAD.0000000000002562
pii: 00002030-202007150-00008
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1347-1358Références
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16:797–808.
Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800–1805.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979–1991.
Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000–2016: a systematic review and meta-analysis. Infection 2017; 45:309–321.
Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually-transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis. AIDS 2015; 29:2335.
van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25:1083–1091.
Boettiger DC, Salazar-Vizcaya L, Dore GJ, Gray RT, Law MG, Callander D, et al. Can Australia reach the World Health Organization hepatitis C elimination goal by 2025 among human immunodeficiency virus-positive gay and bisexual men?. Clin Infect Dis 2020; 70:106–113.
Jin F, Prestage GP, Matthews G, Zablotska I, Rawstorne P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86:25–28.
Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KEA, et al. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions. Hepatology 2016; 64:1856–1869.
Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol 2016; 13:338.
World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva, Switzerland: World Health Organization; 2016.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a nonrandomised, open-label trial. Lancet HIV 2015; 2:e319–e327.
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714–725.
Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis 2016; 62:1072–1080.
Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, et al. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc 2018; 21:e25059.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016; 62:683–694.
Berenguer J, Gil-Martin Á, Jarrin I, Montes ML, Domínguez L, Aldámiz-Echevarría T, et al. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS 2019; 33:685–689.
Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Clin Infect Dis 2017; 64:1154–1162.
Pineda JA, Núñez-Torres R, Téllez F, Mancebo M, García F, Merchante N, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect 2015; 71:571–577.
Marco A, Esteban J, Solé C, Da Silva A, Ortiz J, Roget M, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 2013; 59:45–51.
Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55:1058–1069.
Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017; 66:282–287.
Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, et al. HCV reinfection incidence among individuals treated for recent infection. J Viral Hepat 2017; 24:359–370.
Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013; 27:2551–2557.
Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011; 25:F21–F27.
Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse 2016; 51:1218–1223.
Young J, Potter M, Cox J, Cooper C, Gill J, Hull M, et al. Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study. CMAJ Open 2013; 1:E106.
Hajarizadeh B, Grebely J, Matthews G, Martinello M, Dore G. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat 2018; 25:640–648.
Puhr R, Wright ST, Hoy JF, Templeton DJ, Durier N, Matthews GV, et al. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. Sex Health 2017; 14:345–354.
Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, et al. Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study. Clin Infect Dis 2019.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158:1789–1795.
Iranpour N, Dore G, Martinello M, Matthews G, Grebely J, Hajarizadeh B. Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. Sex Health 2020.
Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: the Australian Trial in Acute Hepatitis C. Int J Drug Policy 2015; 26:976–983.
Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, et al. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study. Int J Drug Policy 2017; 47:230–238.
Artenie AA, Zang G, Daniel M, Fortier E, Jutras-Aswad D, Puzhko S, et al. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. Int J Drug Policy 2017; 47:239–243.
Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, et al. Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: an international study. Clin Infect Dis 2019.
Harris M, Rhodes T. Caring and curing: considering the effects of hepatitis C pharmaceuticalisation in relation to nonclinical treatment outcomes. Int J Drug Policy 2018; 60:24–32.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. Community-level changes in condom use and uptake of HIV preexposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. Lancet HIV 2018; 5:e448–e456.
Chen YH, Guigayoma J, McFarland W, Snowden JM, Raymond HF. Increases in preexposure prophylaxis use and decreases in condom use: behavioral patterns among HIV-negative San Francisco men who have sex with men. AIDS Behav 2019; 23:1841–1845.
Chen YH, Snowden JM, McFarland W, Raymond HF. Preexposure prophylaxis (PrEP) use, seroadaptation, and sexual behavior among men who have sex with men, San Francisco. AIDS Behav 2016; 20:2791–2797.
Sewell J, Cambiano V, Miltz A, Speakman A, Lampe FC, Phillips A, et al. Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton. Sex Transm Infect 2018; 94:494–501.
Sewell J, Cambiano V, Speakman A, Lampe FC, Phillips A, Stuart D, et al. Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study. Int J Drug Policy 2019; 68:54–61.
Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019; 321:1380–1390.
Pradat P, Huleux T, Raffi F, Delobel P, Valantin MA, Poizot-Martin I, et al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS 2018; 32:1077–1082.
Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol 2019; 70:33–39.
Salazar Vizcaya LP, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KEA, et al. Hepatitis C virus transmission among HIV-infected men who have sex with men: modeling the effect of behavioral and treatment interventions. Hepatology 2016; 64:1856–1869.
Huang R, Petoumenos K, Gray RT, McManus H, Dharan N, Guy R, et al. National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort. J Clin Epidemiol 2018; 100:82–91.
Kirby Institute. HIV viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018.
Broady T, Power C, Mao L, Bavinton B, Chan C, Bambridge C, et al. Gay community periodic survey: Sydney 2019. 2019; Sydney: Centre for Social Research in Health, UNSW Sydney, http://doi.org/10.26190/5d5f4bf780c41http://doi.org/10.26190/5d5f4bf780c41. [Accessed 12 November 2019].